We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Committee to Review Merck’s Arcoxia
FDA Advisory Committee to Review Merck’s Arcoxia
April 10, 2007
An increased risk of side effects from Merck’s potential Vioxx successor Arcoxia indicates the drug should not be approved unless it fills an unmet need, an FDA employee told an advisory committee.